HALO US Equity
Halozyme Therapeutics, Inc.Health Care · Biological Products, (No Diagnostic Substances) · CIK 1159036 · FY ends Dec 31$107.62
+2.73 (+2.60%)
USD · as of 2026-08-19 · marketstack
Short interest· FINRA consolidated · settlement 2026-07-31
6 settlement cycles| Shares short | 14.0M |
| % of shares out | 12.4% |
| Days to cover | 8.3 |
| Δ vs 2026-07-15 | +5.5% |
bars = shares short · line = days to cover (own scale)
| Settlement | Shares short | Δ vs prior | Avg daily volume | Days to cover |
|---|
| 2026-07-31 | 14,022,134 | +5.5% | 1,679,119 | 8.3 |
| 2026-07-15 | 13,295,961 | +0.5% | 1,828,707 | 7.3 |
| 2026-06-30 | 13,226,223 | +2.1% | 2,108,787 | 6.3 |
| 2026-06-15 | 12,948,289 | -5.1% | 1,652,526 | 7.8 |
| 2026-05-29 | 13,644,245 | +1.9% | 1,680,327 | 8.1 |
| 2026-05-15 | 13,389,887 | -6.9% | 1,991,771 | 6.7 |
FINRA Rule 4560 · twice monthly, published ~a week later.
Output of a disclosed model — assumptions may be wrong. Research, not investment advice. See the Disclaimer.
